Literature DB >> 9718168

Improvements in pelvic exenteration: factors responsible for reducing morbidity and mortality.

J M Goldberg1, M S Piver, R E Hempling, C Aiduk, L Blumenson, F O Recio.   

Abstract

BACKGROUND: Since pelvic exenteration for the treatment of recurrent gynecologic malignancy first was described, reported rates of morbidity and mortality have declined steadily. However, the factors responsible for this decline have never been clearly delineated.
METHODS: We reviewed the charts of 154 patients who underwent pelvic exenteration for gynecologic malignancy between 1954 and 1994. Charts were abstracted for details of the surgical procedure, pathologic findings, postoperative management, short- and long-term complications, time to recurrence, and overall survival.
RESULTS: Seventy-two patients (47%) experienced 95 identifiable postoperative complications, resulting in death in 22 patients (14%). The rate of infectious complications declined to a statistically significant degree between the first two decades and latter two decades of the study (odds ratio [OR] 0.28. 95% CI 0.11-0.69). The use of routine prophylactic antibiotics was associated with this decline in infectious complications (OR 0.25, 95% CI 0.07-0.83). The use of preoperative subcutaneous heparin was associated with a reduction in thrombotic complications from 5 of 100 patients to 0 of 54 patients (P = .11), as well as a significant reduction in overall risk of complications (OR 0.53, 95% CI 0.33-0.85) and risk of postoperative mortality (OR 0.19, 95% CI 0.05-0.80). There was a significant reduction in overall risk of postoperative complications with both intensive care unit monitoring postoperatively (OR 0.65, 95% CI 0.43-0.99) and routine postoperative monitoring with a pulmonary artery catheter (OR 0.61, 95% CI 0.38-0.98).
CONCLUSIONS: Routine use of prophylactic antibiotics, prophylactic subcutaneous heparin, and intensive postoperative monitoring appear to have reduced morbidity from pelvic exenteration.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9718168     DOI: 10.1007/bf02303857

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Morbidity and outcome of pelvic exenteration in locally advanced pelvic malignancies.

Authors:  Rajaraman Ramamurthy; Amudhan Duraipandian
Journal:  Indian J Surg Oncol       Date:  2012-07-18

2.  Pelvic exenteration for recurrent or persistent cervical cancer: experience of five years at the National Cancer Institute in Mexico.

Authors:  M A Terán-Porcayo; I Zeichner-Gancz; R A C Gomez del-Castillo; A Beltrán-Ortega; G Solorza-Luna
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Outcomes of a bladder preservation technique in female patients undergoing pelvic exenteration surgery for advanced gynaecological tumours.

Authors:  Bernhard Liedl; Wael Y Khoder; Brigitte Ruhdorfer-Metz; Christian G Stief; Raphaela Waidelich
Journal:  Int Urogynecol J       Date:  2014-03-15       Impact factor: 2.894

Review 4.  The role of palliative surgery in gynecologic cancer cases.

Authors:  Joanie Mayer Hope; Bhavana Pothuri
Journal:  Oncologist       Date:  2013-01-08

5.  Pelvic exenteration for advanced and recurrent malignancy.

Authors:  Evita Zoucas; Sven Frederiksen; Marie-Louise Lydrup; Wiking Månsson; Pelle Gustafson; Per Alberius
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

6.  Laparoscopic salvage total pelvic exenteration: Is it possible post-chemo-radiotherapy?

Authors:  H Patel; J V Joseph; A Amodeo; K Kothari
Journal:  J Minim Access Surg       Date:  2009-10       Impact factor: 1.407

7.  [Interdisciplinary aspects of surgery of the pelvis minor and retroperitoneum].

Authors:  R Ackermann; M O Grimm; H G Bender; P Dall; M C Fleisch; W Hohenberger; J Göhl; S Merkel
Journal:  Chirurg       Date:  2004-04       Impact factor: 0.955

8.  Retrospective review of pelvic malignancies undergoing total pelvic exenteration.

Authors:  Maureen P Kuhrt; Ravi J Chokshi; David Arrese; Edward W Martin
Journal:  World J Surg Oncol       Date:  2012-06-15       Impact factor: 2.754

9.  Total pelvic exenteration for primary and recurrent malignancies.

Authors:  F T J Ferenschild; M Vermaas; C Verhoef; A C Ansink; W J Kirkels; A M M Eggermont; J H W de Wilt
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

10.  Pelvic exenteration for colorectal cancer: oncologic outcome in 59 patients at a single institution.

Authors:  Horacio N López-Basave; Flavia Morales-Vásquez; Angel Herrera-Gómez; Alejandro Padilla Rosciano; Abelardo Meneses-García; Juan M Ruiz-Molina
Journal:  Cancer Manag Res       Date:  2012-10-11       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.